Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by University of Oxford.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Medical Research Council
Information provided by:
University of Oxford
ClinicalTrials.gov Identifier:
NCT00222612
First received: September 13, 2005
Last updated: February 2, 2010
Last verified: February 2010

September 13, 2005
February 2, 2010
October 2003
August 2013   (final data collection date for primary outcome measure)
Event free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Event free survival
Complete list of historical versions of study NCT00222612 on ClinicalTrials.gov Archive Site
  • Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Survival
  • Quality of life
Not Provided
Not Provided
 
Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003
Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

A randomised trial for children with acute lymphoblastic leukemia, using the detection of minimal residual disease to define risk groups, aiming to answer the questions:

  1. Can treatment be reduced without compromising efficacy in a MRD-defined low risk group?
  2. Does further post-remission intensification improve outcome for a MRD-defined high risk group?
  3. Measure the Quality of Life impact of the different treatment arms on the children and their families.

Randomisations

Patients will be assigned to MRD risk groups based on day 29 and post consolidation MRD results and randomised as follows:

  1. MRD Low Risk Group (MRD negative at day 29 and week 11 or positive <1 x 10-4 at day 28 and negative at week 11) will continue on previously assigned Regimens (A or B) but randomised between two delayed intensifications and one delayed intensification.
  2. MRD High Risk Group (MRD positive > 1 x 10-4 at day 29) randomised between previously assigned Regimen (A or B) and Regimen C.
  3. MRD Indeterminate Group (No MRD result or MRD positive <1 x 10-4 at day 29 and at week 11) will continue on previously assigned Regimen (A or B) and received two delayed intensifications
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Lymphoblastic Leukemia
  • Other: Reduced intensification
    Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
    Other Name: Removal of second delayed intensification
  • Drug: Standard childhood UK ALL protocol
    No additional treatment to standard protocol.
  • Drug: Intensified treatment including Capizzi maintenance
    Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
  • Active Comparator: A or B with 2DI
    3 or 4 drug induction plus 2 delayed intensifications
    Intervention: Drug: Standard childhood UK ALL protocol
  • Experimental: C plus 2DI
    Intensified treatment including Capizzi maintenance
    Intervention: Drug: Intensified treatment including Capizzi maintenance
  • Experimental: A or B with 1DI
    Reduced intensity treatment
    Intervention: Other: Reduced intensification
Wilson K, Case M, Minto L, Bailey S, Bown N, Jesson J, Lawson S, Vormoor J, Irving J. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia. Haematologica. 2010 Apr;95(4):679-83. Epub 2009 Nov 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2100
August 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion criteria:

Children aged 1 - 18 years with ALL except the following:

Exclusion criteria:

  1. Infants less than a year old should be entered onto the Interfant ALL study.
  2. Children with B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive). Patients with this disease will be eligible for the current UKCCSG B cell NHL/ALL trial.
  3. Children with Philadelphia-positive ALL (t(9;22) or BCR/ABL positive) will start induction therapy on this protocol but transfer to the European Intergroup Protocol as soon as their Philadelphia status is known.

Initially, eligible patients will be stratified into three risk groups based on the following criteria:

  1. Standard risk: all children >1<10 years with a highest white cell count before starting treatment of <50x109/l, and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement.
  2. Intermediate risk: all children ≥10 years old, or with a diagnostic WBC ≥50x109/l (or both) and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement.
  3. High Risk: all children, irrespective of initial risk category, who have a slow early response (SER) as defined below - see section 6 - together with those who have BCR-ABL (induction only), hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement. These patients will not be eligible for MRD randomisation.

Patients will then start treatment according to their risk group as follows:

  1. Standard risk, (around 60-65% of the total): regimen A - three-drug induction.
  2. Intermediate risk, (around 20- 30% of the total): regimen B - four-drug induction.
  3. High risk (around 10-12% of the total): These patients will not be eligible for MRD randomisation. They will be allocated regimen C - four drug induction, augmented BFM consolidation, Capizzi interim maintenance, and two further BFM-style intensification periods of extended duration.

Inclusion criteria for entry into the randomisations:

  1. Standard or Intermediate Risk as defined above.
  2. Morphological Complete Remission (BM1 Marrow) at Day 29 of Induction.
  3. Availability of MRD results at Day 28 and after consolidation therapy.
  4. Informed consent obtained.
  5. Induction given as protocol.

Exclusion criteria for entry into the MRD randomisation:

  1. High Risk as defined above. These patients will receive Regimen C.
  2. Day 28 non-remitters. These patients will receive Regimen C if BM2 or go off-protocol if BM3 (see below for definitions of BM2 and BM3).
  3. MRD Indeterminate Group (No result or MRD positive < 1 x 10-4 at day 28 and after consolidation therapy) will continue on previously assigned therapy.
  4. Sub-optimal induction therapy. The clinical significance of day 28 MRD is uncertain in patients who have received sub-optimal induction therapy. Please discuss these patients with a co-ordinator.
Both
1 Year to 18 Years
No
Contact: Susan Richards, D Phil Sue.Richards@ctsu.ox.ac.uk
United Kingdom
 
NCT00222612
UKALL2003
Yes
Dr Vora, Sheffield University
University of Oxford
Medical Research Council
Principal Investigator: Ajay Vora Sheffield Children's Hospital
University of Oxford
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP